Interleukin-15 cytokine checkpoints in natural killer cell anti-tumor immunity

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2023-10-01 DOI:10.1016/j.coi.2023.102364

Harrison Sudholz , Rebecca B Delconte , Nicholas D Huntington

{"title":"Interleukin-15 cytokine checkpoints in natural killer cell anti-tumor immunity","authors":"Harrison Sudholz , Rebecca B Delconte , Nicholas D Huntington","doi":"10.1016/j.coi.2023.102364","DOIUrl":null,"url":null,"abstract":"<div>Over recent years, the use of immune checkpoint inhibitors (ICI) has progressed to first and second-line treatments in several cancer types, transforming patient outcomes. While these treatments target T cell checkpoints, such as PD-1, LAG3 and CTLA-4, their efficacy can be compromised through adaptive resistance whereby tumors acquire mutations in genes regulating neoantigen presentation by MHC-I [93]. ICI-responsive tumor types such as advanced metastatic melanoma typically have a high mutational burden and immune infiltration; however, most patients still do not benefit from ICI monotherapy for a number of reasons [94]. This highlights the need for novel immunotherapy strategies that evoke the immune control of tumor cells with low neoantigen/MHC-I expression, overcome immune suppressive tumor microenvironments and promote tumor inflammation. In this regard, targeting natural killer (NK) cells may offer a solution to some of these bottlenecks.</div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102364"},"PeriodicalIF":6.6000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791523000833","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Over recent years, the use of immune checkpoint inhibitors (ICI) has progressed to first and second-line treatments in several cancer types, transforming patient outcomes. While these treatments target T cell checkpoints, such as PD-1, LAG3 and CTLA-4, their efficacy can be compromised through adaptive resistance whereby tumors acquire mutations in genes regulating neoantigen presentation by MHC-I [93]. ICI-responsive tumor types such as advanced metastatic melanoma typically have a high mutational burden and immune infiltration; however, most patients still do not benefit from ICI monotherapy for a number of reasons [94]. This highlights the need for novel immunotherapy strategies that evoke the immune control of tumor cells with low neoantigen/MHC-I expression, overcome immune suppressive tumor microenvironments and promote tumor inflammation. In this regard, targeting natural killer (NK) cells may offer a solution to some of these bottlenecks.

查看原文本刊更多论文

白细胞介素-15细胞因子检查点在自然杀伤细胞抗肿瘤免疫中的作用。

近年来，免疫检查点抑制剂（ICI）的使用已发展到几种癌症类型的一线和二线治疗，改变了患者的预后。虽然这些治疗针对T细胞检查点，如PD-1、LAG3和CTLA-4，但它们的疗效可能会因适应性耐药性而受损，即肿瘤获得调节MHC-I新抗原呈递的基因突变[93]。ICI反应性肿瘤类型，如晚期转移性黑色素瘤，通常具有高突变负担和免疫浸润；然而，由于多种原因，大多数患者仍未从ICI单一疗法中获益[94]。这突出了对新抗原/MHC-I表达低的肿瘤细胞的免疫控制、克服免疫抑制性肿瘤微环境和促进肿瘤炎症的新免疫治疗策略的需求。在这方面，靶向自然杀伤细胞（NK）可能为解决其中一些瓶颈提供了解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.